Travere Therapeutics' Q2 product sales up 82%

Travere Therapeutics

06/08/2025 21:21

Overview

Travere Q2 2025 product sales rise 82% to $94.8 mln, driven by FILSPARI

Total revenue for Q2 2025 reaches $114.4 mln, includes $17.5 mln milestone

Net loss narrows to $12.8 mln from $70.4 mln in Q2 2024

Outlook

Travere expects August 2025 PDUFA date for FILSPARI REMS modification

Company anticipates January 2026 FDA decision on FILSPARI for FSGS

Result Drivers

FILSPARI SALES GROWTH - U.S. net product sales of FILSPARI grew 165% year-over-year to $71.9 mln, driven by increased momentum in the IgAN market

MILESTONE PAYMENT - Total revenue includes $17.5 mln milestone payment from CSL Vifor

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Sales
$94.84 mln
Q2 EPS
-$0.14
Q2 Net Income
-$12.76 mln
Q2 Operating Expenses
$127.10 mln
Q2 Operating Income
-$12.65 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Travere Therapeutics Inc is $30.00, about 44.4% above its August 5 closing price of $16.68

Press Release: ID:nBw227grPa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)